How to Get Alprostadil (Caverject/MUSE) in Nebraska

What Alprostadil Is and Why It Is Prescribed for Erectile Dysfunction

Alprostadil is a synthetic prostaglandin E1 (PGE1) that relaxes smooth muscle in the corpus cavernosum, dilates cavernosal arteries, and produces an erection within 5 to 20 minutes. It is prescribed when oral phosphodiesterase type-5 (PDE5) inhibitors, such as sildenafil or tadalafil, have failed or are contraindicated. The FDA approved Caverject for intracavernosal injection in 1995 and MUSE for intraurethral delivery in 1996, making alprostadil one of the longest-standing second-line treatments for erectile dysfunction (ED) in the United States.

The key trial published in the New England Journal of Medicine by Linet and Ogrinc (1996, N=296) showed that intracavernosal alprostadil produced successful intercourse in 94% of injection attempts versus 10% with placebo, with a mean effective dose of 17.8 mcg [1]. Separately, a crossover study published in the International Journal of Impotence Research found intraurethral alprostadil (MUSE) produced erections sufficient for intercourse in approximately 65% of men who had previously failed PDE5 inhibitor therapy [2]. The American Urological Association (AUA) 2018 guideline on ED classifies alprostadil as a second-line therapy and states: "Intracavernosal injection therapy should be offered to patients with erectile dysfunction who do not respond to or cannot use PDE5 inhibitors" [3].

Alprostadil acts through adenylate cyclase, increasing intracellular cyclic AMP independently of the nitric oxide pathway, which is why it remains effective in men with severe vascular disease, post-prostatectomy nerve damage, or diabetes-related neuropathy. A 2021 review in Translational Andrology and Urology reported that intracavernosal alprostadil achieves response rates of 70 to 90% even in men with organic ED of multiple etiologies [4].

Nebraska Telehealth Rules and Alprostadil Prescribing

Nebraska permits telehealth prescribing of alprostadil by any licensed prescriber who holds active Nebraska authority. The Nebraska Uniform Credentialing Act requires that a prescriber establish a valid patient-provider relationship before issuing any prescription, and that requirement can be met through a synchronous audio-video encounter [5]. A text-only or asynchronous questionnaire alone does not satisfy Nebraska's standard of care for a controlled or high-risk prescription.

Telehealth providers offering alprostadil in Nebraska must hold either a Nebraska medical license or a Nebraska telehealth registration if licensed in another state. Nebraska joined the Interstate Medical Licensure Compact (IMLC), which allows qualifying physicians in compact states to obtain expedited Nebraska licensure [6]. Nurse practitioners and physician assistants with prescriptive authority can also prescribe alprostadil under Nebraska law, provided their scope-of-practice agreement or collaborative practice agreement permits it.

The HealthRX Nebraska Alprostadil Access Pathway outlines four sequential steps most patients follow:

1. Initial telehealth or in-person visit. The provider reviews medical history, current medications, cardiovascular status, and prior ED treatment failures.
2. Lab work and baseline assessment. Testosterone, fasting glucose, HbA1c, lipid panel, and sometimes a penile duplex Doppler ultrasound are ordered to document the ED etiology and rule out contraindications.
3. First-dose injection training. Nebraska clinical standards require that a patient's first dose be administered or directly supervised by a licensed provider. Many telehealth platforms coordinate this with a local urology office or primary care clinic.
4. Ongoing prescription and pharmacy fulfillment. Subsequent refills may be managed entirely via telehealth if the patient tolerates the initial dose without priapism or other adverse events.

The FDA's Risk Evaluation and Mitigation Strategy guidance for intracavernosal vasoactive agents emphasizes that patients must be trained on self-injection technique and warned to seek emergency care for any erection lasting more than four hours [7].

Labs and Clinical Workup Required Before Prescribing in Nebraska

Before any Nebraska provider, in-person or telehealth, writes an alprostadil prescription, a baseline clinical workup is standard of care. The AUA ED guideline recommends the following minimum evaluation: a focused medical and sexual history, a physical examination (or telehealth-adapted equivalent), serum total testosterone, fasting glucose or HbA1c, and a lipid panel [3]. Additional testing depends on the clinical picture.

Serum testosterone is non-negotiable. Hypogonadism (total testosterone below 300 ng/dL per the AUA and Endocrine Society thresholds) often co-exists with ED, and correcting testosterone deficiency may improve PDE5 inhibitor response before alprostadil is needed [8]. A 2020 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (N=2,671 men) found that testosterone therapy alone improved erectile function scores by a mean of 2.9 points on the IIEF-5 scale, though most men with severe organic ED still required additional pharmacotherapy [9].

HbA1c is ordered because uncontrolled diabetes is one of the most common reversible contributors to vascular and neuropathic ED. Fasting lipids identify dyslipidemia as a treatable vascular risk factor. In men over 40 or with cardiovascular symptoms, the Princeton Consensus Panel III recommends a cardiovascular risk stratification step before any vasoactive therapy is initiated [10]. High-risk patients, those with unstable angina, recent myocardial infarction within 6 weeks, or uncontrolled hypertension above 170/100 mmHg, should be stabilized before alprostadil is prescribed.

Penile duplex Doppler ultrasound is not universally required but becomes important when arterial versus venogenic insufficiency needs to be distinguished, particularly before considering penile prosthesis surgery as a next step. Nebraska academic centers, including the University of Nebraska Medical Center urology department in Omaha, offer this diagnostic service.

How to Find a Prescriber in Nebraska (In-Person and Telehealth)

Nebraska has approximately 35 board-certified urologists practicing in the state, concentrated in Omaha and Lincoln, with limited access in rural regions such as the Sandhills and Panhandle [11]. For patients outside metropolitan areas, telehealth is the practical route to a timely alprostadil consultation.

Several national telehealth platforms hold Nebraska prescribing authority and can manage alprostadil prescriptions, provided the patient completes a video visit rather than a questionnaire-only flow. HealthRX providers licensed in Nebraska can conduct the initial evaluation, coordinate first-dose training with a local partner clinic, and manage refills. When selecting any telehealth service, confirm three things: the prescriber holds an active Nebraska license or IMLC authorization, the platform supports Schedule-exempt prescription forwarding to a Nebraska-licensed pharmacy, and the service can support first-dose training.

Primary care physicians and internal medicine providers in Nebraska can also prescribe alprostadil if they have experience with injection training. In practice, many primary care providers refer to urology for the first-dose visit and then co-manage ongoing prescriptions. Family medicine physicians account for a meaningful share of ED prescriptions in rural Nebraska counties where urology access is limited [11].

Nebraska Pharmacies and 503A Compounding for Alprostadil

Branded Caverject Impulse (Pfizer) and generic alprostadil injection kits are available at retail pharmacies in Nebraska, including large chains such as Walgreens, CVS, and HyVee, as well as independent pharmacies. MUSE urethral suppositories are available at most retail pharmacies by special order. Cash prices for branded Caverject range from $90, $200 per dual-chamber syringe kit (10 mcg or 20 mcg) without insurance, based on current GoodRx Nebraska data.

Nebraska 503A compounding pharmacies are licensed by the Nebraska Department of Health and Human Services (DHHS) Pharmacy Division and may compound patient-specific alprostadil formulations on a valid prescription [12]. Compounded alprostadil is commonly prepared in multi-dose vials at concentrations such as 20 mcg/mL or 40 mcg/mL, often with papaverine or phentolamine added to create combination vasoactive injection therapy (known as bi-mix or tri-mix). Combination formulations can reduce the alprostadil dose needed per injection and thereby lower the incidence of injection-site pain, which occurs in roughly 11% of men using alprostadil monotherapy per the package insert data [7].

Nebraska 503A pharmacies may ship compounded alprostadil to patients within the state on a valid prescription. They may not ship across state lines under USP 795 and 797 compounding standards unless the receiving state permits it. Patients transferring from another state should confirm their Nebraska prescriber re-issues the prescription to a Nebraska-licensed pharmacy or compounding facility.

The FDA has not approved compounded alprostadil combinations (bi-mix, tri-mix) as finished drug products. Patients should understand that compounded formulations lack FDA-reviewed clinical data for the specific combination, though individual components have established safety profiles [13]. A 2022 analysis published in the Journal of Sexual Medicine found that tri-mix (alprostadil plus papaverine plus phentolamine) produced erections sufficient for intercourse in 92% of men with organic ED compared to 79% for alprostadil monotherapy (P<0.01, N=183) [14].

Insurance, Prior Authorization, and Nebraska Medicaid

Nebraska Medicaid does not cover alprostadil for erectile dysfunction. This exclusion follows Centers for Medicare and Medicaid Services (CMS) guidance that treats ED medications as lifestyle drugs, placing them outside mandatory Medicaid benefit categories [15]. Patients on Nebraska Medicaid will pay the full out-of-pocket cost unless they have a Medicare Part D plan with optional supplemental drug benefits or a separate private insurance rider.

Private insurance coverage varies considerably. Many commercial plans in Nebraska cover alprostadil with prior authorization (PA). A standard PA submission for alprostadil in Nebraska typically requires:

• Documentation of an erectile dysfunction diagnosis with ICD-10 code N52.x
• Confirmation that at least two PDE5 inhibitors (e.g., sildenafil 100 mg, tadalafil 20 mg) were tried and failed or are medically contraindicated
• Prescriber attestation that alprostadil is medically necessary
• Supporting labs (testosterone level, HbA1c if diabetic)
• In some cases, a note from a urologist confirming second-line therapy is appropriate

The Blue Cross Blue Shield of Nebraska medical policy for ED medications, updated in 2024, specifies that intracavernosal alprostadil is covered under the pharmacy benefit when the above criteria are met, with a quantity limit of 12 doses per 30 days [16]. Patients whose PA is denied have the right to appeal under Nebraska Insurance Department regulations and, if applicable, under the Affordable Care Act's external review provisions.

Manufacturer patient assistance programs may reduce costs for eligible low-income patients. Pfizer's Caverject assistance program offers free or reduced-cost medication for patients with household incomes below 400% of the federal poverty level who lack adequate insurance coverage.

Dosing, Administration, and Safety Considerations

Alprostadil dosing for intracavernosal injection starts at 1.25 to 2.5 mcg and is titrated upward in a clinical setting until an erection of adequate rigidity lasting no more than 60 minutes is achieved. The maximum recommended single dose is 40 mcg. For MUSE suppositories, the titration range is 125, 1 to 000 mcg administered 5 to 10 minutes before intercourse.

The most serious adverse event is priapism, an erection lasting four hours or longer, which occurs in approximately 0.4% of injections per FDA label data [7]. Priapism is a urologic emergency. Men must be counseled explicitly to go to an emergency department if an erection persists beyond four hours, where aspiration or intracavernosal sympathomimetic injection (phenylephrine 200 to 500 mcg) is the standard treatment per AUA guidelines [3]. The second most common adverse event is penile pain, reported in roughly 11% of injection cycles. Penile fibrosis or scarring occurs in about 3% of long-term users, typically with injection frequencies exceeding three times per week [7].

For MUSE, urethral burning is the most common complaint, reported by approximately 36% of users in the original phase III trial data [17]. Hypotension and syncope occur in roughly 3% of MUSE users, particularly when alprostadil is absorbed systemically. Patients are advised to sit or lie down for 10 minutes after administration. A vaginal burning sensation in the female partner has been reported and may warrant condom use during MUSE therapy.

Drug interactions are limited but relevant. Concurrent use of antihypertensives increases the risk of hypotension. Patients on anticoagulants face a modestly higher bleeding risk at injection sites. Men using any nitrate preparation should discuss the combination with their provider, though alprostadil's mechanism is nitric-oxide-independent and the absolute risk is lower than with PDE5 inhibitors and nitrates [8].

A 2019 Cochrane systematic review of intracavernosal prostaglandin E1 (N=12 trials, 1,520 participants) confirmed that alprostadil is more effective than placebo for achieving erections sufficient for intercourse (relative risk 5.14 to 95% CI 3.72, 7.09) and that penile pain was the primary reason for discontinuation [18]. Long-term adherence at 12 months ranges from 50 to 70% in observational studies, with pain and the injection process itself being the principal barriers.

Transferring an Existing Alprostadil Prescription to Nebraska

Patients relocating to Nebraska who already have an alprostadil prescription from another state need a new prescription issued by a Nebraska-licensed provider. Nebraska pharmacies cannot fill an out-of-state controlled or prescription drug unless the prescribing provider holds active Nebraska licensure. Because alprostadil is not a DEA-scheduled controlled substance, the transfer process is administratively simpler than for opioids or stimulants, but the new-prescriber requirement still applies under Nebraska pharmacy law [12].

The practical steps are: schedule a telehealth or in-person visit with a Nebraska-licensed provider, bring prior prescription records and any prior authorization approval letters, and request that the new provider submit a fresh prescription to a Nebraska pharmacy. If prior authorization was previously approved with a commercial insurer, the insurer may honor the existing PA for the remainder of the approval period if the plan is the same, but this requires a call to the plan's pharmacy benefits manager to confirm.

Patients using compounded tri-mix from an out-of-state 503A pharmacy must transition to a Nebraska 503A pharmacy, since interstate shipment of patient-specific compounded products is restricted under federal and Nebraska state law [12].

Who Can Prescribe Alprostadil in Nebraska

Any Nebraska-licensed physician (MD or DO), advanced practice registered nurse (APRN) with prescriptive authority, or physician assistant (PA) with prescriptive authority may prescribe alprostadil. Nebraska APRNs hold independent prescriptive authority following a minimum of 2 to 000 hours of collaborative practice, after which they may prescribe Schedule II, V controlled substances and all non-scheduled prescription drugs without a collaborating physician [19]. Alprostadil is a non-scheduled prescription drug, so APRNs at any stage of their practice period may prescribe it in Nebraska.

PAs in Nebraska prescribe under a practice agreement with a supervising physician. That agreement must explicitly permit prescribing of vasoactive medications for ED if the PA is to issue alprostadil independently [19]. Patients seeing a PA via telehealth should confirm the PA's practice agreement covers this drug class before the visit.

Urologists remain the most experienced prescribers for alprostadil and are best positioned to perform first-dose titration, manage priapism events, and assess for penile fibrosis on follow-up. The AUA recommends that all patients starting injection therapy receive formal injection training from a qualified provider, a standard that applies equally to prescriptions originating from telehealth visits [3].